Wall Street analysts forecast that Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) will report earnings per share of ($0.57) for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Aquinox Pharmaceuticals’ earnings. Aquinox Pharmaceuticals posted earnings per share of ($0.39) in the same quarter last year, which would indicate a negative year over year growth rate of 46.2%. The firm is expected to report its next earnings results on Tuesday, May 9th.
On average, analysts expect that Aquinox Pharmaceuticals will report full year earnings of ($2.37) per share for the current fiscal year, with EPS estimates ranging from ($2.43) to ($2.30). For the next fiscal year, analysts anticipate that the company will post earnings of ($2.40) per share. Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Aquinox Pharmaceuticals.
Aquinox Pharmaceuticals (NASDAQ:AQXP) last announced its earnings results on Thursday, March 9th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.51) by $0.03.
A number of research analysts recently weighed in on AQXP shares. Cantor Fitzgerald reissued an “overweight” rating on shares of Aquinox Pharmaceuticals in a research report on Tuesday, March 21st. Zacks Investment Research lowered shares of Aquinox Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 17th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $21.17.
Hedge funds have recently made changes to their positions in the company. Eventide Asset Management LLC bought a new stake in shares of Aquinox Pharmaceuticals during the fourth quarter valued at approximately $2,889,000. BlackRock Advisors LLC raised its stake in shares of Aquinox Pharmaceuticals by 31.1% in the third quarter. BlackRock Advisors LLC now owns 530,373 shares of the company’s stock valued at $7,086,000 after buying an additional 125,798 shares in the last quarter. Baker BROS. Advisors LP bought a new stake in shares of Aquinox Pharmaceuticals during the third quarter valued at approximately $140,762,000. BlackRock Group LTD raised its stake in shares of Aquinox Pharmaceuticals by 15.9% in the third quarter. BlackRock Group LTD now owns 232,002 shares of the company’s stock valued at $3,100,000 after buying an additional 31,902 shares in the last quarter. Finally, RA Capital Management LLC raised its stake in shares of Aquinox Pharmaceuticals by 29.6% in the third quarter. RA Capital Management LLC now owns 2,191,977 shares of the company’s stock valued at $29,285,000 after buying an additional 500,000 shares in the last quarter. 97.78% of the stock is currently owned by institutional investors and hedge funds.
Shares of Aquinox Pharmaceuticals (NASDAQ:AQXP) traded down 0.77% on Monday, hitting $14.25. 134,001 shares of the company’s stock were exchanged. Aquinox Pharmaceuticals has a 12 month low of $6.01 and a 12 month high of $19.97. The stock’s 50 day moving average is $16.45 and its 200 day moving average is $15.42. The firm’s market cap is $333.78 million.
About Aquinox Pharmaceuticals
Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company operates in the segment of identification and development of therapeutics in disease areas of inflammation and immuno-oncology.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/0-57-earnings-per-share-expected-for-aquinox-pharmaceuticals-inc-aqxp-this-quarter/1739596.html
Receive News & Ratings for Aquinox Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.